- Home
- PSNYW vs FHTX Comparison
PSNYW vs FHTX Comparison
Compare PSNYW & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNYW | FHTX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Sweden | United States |
| Employees | 1686 | N/A |
| Industry | Auto Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.9M | 323.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSNYW | FHTX |
|---|---|---|
| Price | $2.68 | $4.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 5.5K | ★ 138.7K |
| Earning Date | 03-06-2025 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,034,261,000.00 | $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | $79.49 | $20.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $0.14 | $3.27 |
| 52 Week High | $7.50 | $6.95 |
Technical Indicators
Market Signals| Indicator | PSNYW | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 52.98 |
| Support Level | $2.45 | $3.59 |
| Resistance Level | $3.50 | $4.64 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 23.68 | 88.00 |
Price Performance
Historical ComparisonAbout PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.